LGM Pharma Commits $15 Million to Texas and Colorado Facilities to Bolster Domestic Drug Manufacturing Capacity

LGM Pharma expands Texas and Colorado facilities with a $15M investment to boost domestic production of specialized OSD and suppository drug products.

By: AXL Media

Published: Mar 19, 2026, 10:56 AM EDT

Source: Information for this report was sourced from LGM Pharma

Strengthening the Domestic Pharmaceutical Backbone

LGM Pharma has initiated the second phase of its aggressive growth strategy by committing an additional $9 million to enhance its American manufacturing footprint. This latest capital infusion targets the company's existing facilities in Texas and Colorado, elevating the total investment to $15 million following an initial $6 million expansion in 2025. According to Chief Executive Officer Prasad Raje, the move is a direct response to the pharmaceutical industry's growing need for integrated partners that can manage the full product lifecycle within the United States, thereby reducing reliance on volatile international logistics.

Specialized Expansion in the Texas Health Corridor

The Rosenberg, Texas, facility is slated for a $4 million upgrade specifically designed to capture the growing market for specialized drug delivery systems. These enhancements will expand commercial-scale manufacturing suites for suppositories, a sector seeing significant growth within women’s health portfolios. Beyond mere production volume, the investment will bolster the site's research and development capabilities, allowing for more sophisticated formulation and scale-up of solutions, suspensions, and semi-solid medications. LGM Pharma confirmed that the Rosenberg site will remain fully operational during the construction phase to ensure no disruption to current client orders.

Capitalizing on the Oral Solid Dose Market

In Colorado Springs, a $5 million investment is being directed toward expanding the production of niche, high-value oral solid dose (OSD) products. This facility, which serves as LGM Pharma’s center of excellence for OSD development, will now increase its capacity for orally disintegrating tablets (ODTs) to meet a surging domestic demand. This strategic pivot is well-timed, as the global OSD contract manufacturing market reached a valuation of $43.65 billion in 2024. With North America currently representing over 40% of global OSD manufacturing activity, LGM Pharma is positioning itself to capture a larger share of this high-value domestic sector.